"Sirolimus" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.
| Descriptor ID |
D020123
|
| MeSH Number(s) |
D02.540.505.760
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Sirolimus".
Below are MeSH descriptors whose meaning is more specific than "Sirolimus".
This graph shows the total number of publications written about "Sirolimus" by people in this website by year, and whether "Sirolimus" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 1 | 2 |
| 2004 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 3 | 1 | 4 |
| 2010 | 3 | 1 | 4 |
| 2011 | 4 | 1 | 5 |
| 2012 | 3 | 0 | 3 |
| 2013 | 0 | 1 | 1 |
| 2014 | 2 | 1 | 3 |
| 2015 | 0 | 1 | 1 |
| 2016 | 2 | 0 | 2 |
| 2017 | 27 | 22 | 49 |
| 2018 | 28 | 23 | 51 |
| 2019 | 10 | 8 | 18 |
| 2020 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Sirolimus" by people in Profiles.
-
mTORC1 hyperactivation in lymphangioleiomyomatosis leads to ACE2 upregulation in type II pneumocytes: implications for COVID-19. Eur Respir J. 2021 02; 57(2).
-
mTOR inhibition: a double-edged sword in patients with COVID-19? Hum Cell. 2021 Mar; 34(2):698-699.
-
Coronavirus Disease 2019 in Kidney Transplant Recipients: Single-Center Experience and Case-Control Study. Transplant Proc. 2021 May; 53(4):1187-1193.
-
Rapamycin as a potential repurpose drug candidate for the treatment of COVID-19. Chem Biol Interact. 2020 Nov 01; 331:109282.
-
How anti-ageing drugs could boost COVID vaccines in older people. Nature. 2020 10; 586(7829):352-354.
-
mTORC inhibitor Sirolimus deprograms monocytes in "cytokine storm" in SARS-CoV2 secondary hemophagocytic lymphohistiocytosis- like syndrome. Clin Immunol. 2020 09; 218:108539.
-
Genomic discovery of an evolutionarily programmed modality for small-molecule targeting of an intractable protein surface. Proc Natl Acad Sci U S A. 2020 07 21; 117(29):17195-17203.
-
From causes of aging to death from COVID-19. Aging (Albany NY). 2020 06 12; 12(11):10004-10021.
-
Liver transplant immunosuppression during the covid-19 pandemic. Gastroenterol Hepatol. 2020 Oct; 43(8):457-463.
-
Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19. Clin Immunol. 2020 07; 216:108464.